NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

2020475 citationsJournal Articlebronze Open Access

Authors

John A. Thompson · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Bryan J. Schneider · University of Michigan–Ann Arbor

Julie R. Brahmer · Sidney Kimmel Comprehensive Cancer Center

Stephanie Andrews · Moffitt Cancer Center

Philippe Armand · Dana-Farber Brigham Cancer Center

Shailender Bhatia · Fred Hutch Cancer Center

Lihua E. Budde

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Neutropenia and Cancer Infections Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the National Comprehensive Cancer Network

Volume 18, Issue 3, pp. 230-241

DOI: 10.6004/jnccn.2020.0012

Field-Weighted Citation Impact: 25.72

Command Palette